These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 38831048)
1. [Chronic obstructive pulmonary disease (COPD): eosinophilia and novel drug therapies]. Biener L; Pizarro C; Skowasch D Inn Med (Heidelb); 2024 Jul; 65(7):738-745. PubMed ID: 38831048 [TBL] [Abstract][Full Text] [Related]
2. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061 [TBL] [Abstract][Full Text] [Related]
3. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Tashkin DP; Wechsler ME Int J Chron Obstruct Pulmon Dis; 2018; 13():335-349. PubMed ID: 29403271 [TBL] [Abstract][Full Text] [Related]
4. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility. Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW Lung; 2006; 184(4):217-22. PubMed ID: 17006748 [TBL] [Abstract][Full Text] [Related]
5. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032 [TBL] [Abstract][Full Text] [Related]
6. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Pavord ID; Lettis S; Anzueto A; Barnes N Lancet Respir Med; 2016 Sep; 4(9):731-741. PubMed ID: 27460163 [TBL] [Abstract][Full Text] [Related]
7. Eosinophilic airway inflammation in COPD. Saha S; Brightling CE Int J Chron Obstruct Pulmon Dis; 2006; 1(1):39-47. PubMed ID: 18046901 [TBL] [Abstract][Full Text] [Related]
8. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028 [TBL] [Abstract][Full Text] [Related]
9. Stepwise management of COPD: What is next after bronchodilation? Miravitlles M; Matsunaga K; Dreher M Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381 [TBL] [Abstract][Full Text] [Related]
10. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. van Geffen WH; Tan DJ; Walters JA; Walters EH Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551 [TBL] [Abstract][Full Text] [Related]
11. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids. Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449 [TBL] [Abstract][Full Text] [Related]
12. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464 [TBL] [Abstract][Full Text] [Related]
13. Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD. D'Urzo A; Singh D; Garcia Gil E NPJ Prim Care Respir Med; 2017 Feb; 27(1):13. PubMed ID: 28235977 [TBL] [Abstract][Full Text] [Related]
14. Clinical burden of illness among patients with severe eosinophilic COPD. Müllerová H; Meeraus WH; Galkin DV; Albers FC; Landis SH Int J Chron Obstruct Pulmon Dis; 2019; 14():741-755. PubMed ID: 31114180 [No Abstract] [Full Text] [Related]
15. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Tashkin DP; Strange C Int J Chron Obstruct Pulmon Dis; 2018; 13():2587-2601. PubMed ID: 30214177 [TBL] [Abstract][Full Text] [Related]
16. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. Puhan MA; Bachmann LM; Kleijnen J; Ter Riet G; Kessels AG BMC Med; 2009 Jan; 7():2. PubMed ID: 19144173 [TBL] [Abstract][Full Text] [Related]
17. Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis. Oshagbemi OA; Odiba JO; Daniel A; Yunusa I Curr Drug Targets; 2019; 20(16):1670-1679. PubMed ID: 31393244 [TBL] [Abstract][Full Text] [Related]
18. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739 [TBL] [Abstract][Full Text] [Related]
19. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD). Oshagbemi OA; Franssen FME; van Kraaij S; Braeken DCW; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Vries F COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850 [TBL] [Abstract][Full Text] [Related]